Sentences with phrase «new asthma development»
Not exact matches
This updated volume also offers new insights on prematurity, sleep patterns, early communication, toilet training, co-sleeping, play and learning, SIDS, cognitive development and signs of developmental delay, childcare, asthma, a child's immune system, and safety.
http://www.nantolbert.org/
Understanding the role the brain plays in conditions linked to inflammation — such as asthma, arthritis, cardiovascular disease and depression — will help in the development of new treatments to combat them, says Slavich.
The outcomes of this work open new avenues of research with the goal of elucidating the biological mechanisms underlying asthma in relationship with environmental exposures and to promote the development of new therapies.
This study opens new avenues of research aiming at integrating genomic and epigenomic data together with environmental exposures in order to elucidate the physio - pathological mechanisms underlying asthma and to promote the development of new therapies.
«This work represents a mechanistic insight that could lead to the development of a new therapeutic approach for preventing asthma.»
Research demonstrates that blocking the action of two pro-inflammatory molecules significantly reduces symptoms of allergic asthma in mice, which could lead to development of a new treatment for people with a severe form of the condition.
Professor Fallon said: «This identification of an early stage cellular checkpoint that can act as a break on allergic responses has important implications for the development of new therapeutic approaches for asthma and other allergic diseases.»
Exposure to ozone during childhood can also impair normal lung growth and development and may contribute to new asthma, which can start at any age.
Professor Bradding, who is a Professor of Respiratory Medicine at the University of Leicester and Consultant Respiratory Physician at Leicester's Hospitals, said: «The most exciting thing about finding these biological variations underpinning the differences between mild asthma and moderate and severe asthma is that the statistical methods if further developed could lead to the development of new, targeted treatments for subtypes of asthma, thus allowing the right asthma treatments to be matched to different patients.
The NIHR Leicester Respiratory Biomedical Research Unit — a partnership between the University of Leicester and Leicester's Hospitals — focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
Natural killer cells serve important roles in clearing non-type 2 inflammatory cells, so identification of a defect in NK cell function in severe asthma provides a window for the development of new therapeutic approaches.
«We know that mothers» exposure to air pollution during pregnancy can affect lung development of their babies and lead to subsequent respiratory disorders, including asthma, although little is known about whether timing of the exposure is important to consider,» said lead author Yueh - Hsiu Mathilda Chiu, ScD, from the Department of Pediatrics at Icahn School of Medicine at Mount Sinai in New York.
«While we studied patients with allergic asthma, this research opens the door for the development of new treatments not only for this population, but for those diagnosed with severe asthma as well.»
This translates into more accurate diagnostics, new therapy strategies and the development of patient - focused drugs that can target the different subgroups of asthma.
A new digital «map» detailing different mechanisms that contribute to the development of asthma could help researchers redefine the disease.
Calling their compound a new therapeutic candidate for people with severe asthma and other chronic airway diseases, researchers say with additional research and development their discovery could lead to future clinical trials for asthma, Cystic Fibrosis and Chronic Obstructive Pulmonary Disease (COPD).
«This is sure to spark major new efforts toward the development of vaccines and antiviral drugs, particularly for the prevention of asthma.»
Development of advanced preclinical models are needed to further elucidate the complex mechanisms underlying asthma exacerbation and investigate new therapeutic strategies.
Research into lung disease has yielded many life - changing results, such as the development of new effective asthma treatment, the increased success of lung transplants, better treatments for cystic fibrosis, and proving the link between smoking and lung cancer.
Stephen Alexander, UK - Cannabinoid receptors, transporters, endocannabinoid turnover, hydrogen sulphide turnover Arthur Christopoulos, Australia (GPCRs Liaison)- G protein - coupled receptors; analytical pharmacology; allosteric modulation; biased agonism; drug discovery; neuropharmacology John Cidlowski, USA (NHRs Liaison)- Glucocorticoid receptor signaling; apoptosis and the immune system Anthony P. Davenport, UK (Chair Evolving Pharmacology, GPCRs Liaison) Doriano Fabbro, Switzerland - Kinases and their biology, kinase inhibitors, drug discovery, pharmacology of drugs (kinase inhibitors) in the indication oncology, biology of oncology Kozo Kaibuchi, Japan Yoshikatsu Kanai, Japan - Transporters, amino acid signals, epithelial function, cancer biology Francesca Levi - Schaffer, Israel - eosinophils and mast cells as effector cells in allergic inflammation: characterization of new receptors / ligands, hypoxia / angiogenesis and eosinophils, asthma, atopic dermatitis, allergic rhinitis, immunopharmacological modulation of allergic diseases by bispecific recombinant antibodies, bacteria interactions with eosinophils and mast cells, the allergic effector unit, mast cell derived tumors: new antibody based treatment, the allergic inflammation and the resolvome, non IgE - mediated mast cell activation in diseases Eliot H. Ohlstein, USA (Editor)- Drug discovery and development, urogenital biology, cardiovascular / metabolic medicine John A. Peters, UK (LGICs Liaison) Alex Phipps, UK - Oncology, Clinical Pharmacology, Biologics and Immunotherapy Joerg Striessnig, Austria (VGICs Liaison)- Physiology, pharmacology and pathophysiological role of voltage-gated calcium channels
One of the principal goals in the development of new methods for treating asthma is therefore to identify non-steroidal drugs that can effectively control the inflammatory response underlying asthma symptoms.
The results of the Immune Tolerance Network's (ITN) «Learning Early About Peanut» (LEAP), discussed on February 23, 2015 at the American Academy of Allergy, Asthma & Immunology Annual Meeting and published in the New England Journal of Medicine, demonstrate that consumption of a peanut - containing snack by infants who are at high - risk for developing peanut allergy prevents the subsequent development of allergy.